However, current evidence-based consensus guidelines recommend the consideration of NAC for most patients with triple-negative (TN) and HER2-positive (HER2+) breast cancers, specifically those with positive lymph nodes (N1-3) and/or tumours measuring 2 cm (cT2) or larger [3,4,5,6]. The gene discussed is ERBB2; the disease is breast cancer.